

# Partnering in Technologies



Our goal is to discover and develop breakthroughs in animal health for diseases with significant unmet need. To achieve this, we're investing in cutting-edge science and technology to expand and accelerate our drug discovery for the next generation of treatments and preventive therapies. Beyond our innovative and comprehensive portfolio of products and services to prevent disease and improve the health and well-being of animals, we're identifying and translating the most promising technology innovations into impactful applications across a broad range of fields.

Collaborations with innovative and entrepreneurial partners are helping solve the biggest challenges in animal health. We believe that by working together we can bring critical diversity to innovation and accelerate the next wave of therapeutics that will transform the health and well-being of animals now and in generations to come.


## Partnering Interests

Actively pursuing new partnerships in our research focus areas and open to a variety of partnership models to explore:

- Novel pharmaceutical delivery technologies
- Long-acting delivery formulations
- Manufacturing technologies e.g., cell lines, technical stabilization technologies, innovative packaging solutions, improvements for in process controls
- Biotherapeutic technologies including vaccine platforms/immunostimulatory adjuvants.

## Research Focus

- Leveraging expertise in a broad range of formulation and biological delivery technologies
- Applying species-specific insights to implement novel delivery and formulation solutions
- Identifying and translating the most promising technology innovations into impactful applications across a variety of research fields.



## Collaboration Driving Innovation

- Growing our global community of innovation partners
- Multiple collaborations advancing new therapies
- Long-term partnerships for the next generation of breakthroughs

## Investing in Animal Health Innovation



**>€450 million**

R&D for new medicines



**Global**

R&D presence in Europe, N. America, Asia



**~1,200**

staff in R&D facilities worldwide



**>250**

innovation collaborations

## Leveraging synergies with Human Pharma



Exchanging scientific knowledge and expertise



Access to data, models and novel technologies

## Meet the Team



**Xiaoping Cui**

[xiaoping.cui@boehringer-ingelheim.com](mailto:xiaoping.cui@boehringer-ingelheim.com)



**Eva Lauermann**

[eva.lauermann@boehringer-ingelheim.com](mailto:eva.lauermann@boehringer-ingelheim.com)

